Thank you
This live web event has ended. Thank you for attending.
This live web event has ended. Thank you for attending.
After obtaining his PhD at the University of
Texas, Ken Stover started his postgraduate career at the Walter Reed Army
Institute of Research (WRAIR) in Washington D.C. as a Captain in the U.S. Army,
where he worked on the molecular biology, pathogenesis and discovery of protective
antigens for infectious disease vaccines.
Ken joined MedImmune in 1989 where he led efforts to develop a new live-vectored
vaccine platform for multiple infectious diseases based on the BCG tuberculosis
vaccine. Ken’s efforts in the molecular
microbiology of tuberculosis transitioned from vaccine research to small
molecule drug discovery in 1993 when he joined Seattle based biotech PathoGenesis
to lead their drug discovery efforts for new tuberculosis drugs and
investigations into bacterial pathogenesis and drug resistance. At PathoGenesis, a new in vitro-in vivo drug screening strategy led to the identification
of a novel antitubercular clinical candidate, PA824 (Pretomanid), now in Phase
3 clinical studies. At PathoGenesis, Ken also directed functional genomic work
on Staphylococcus aureus and Pseudomonas aeruginosa and the P. aeruginosa genome project. He joined Pfizer’s Ann Arbor laboratories in 2002
where he directed the Molecular Science’s biology efforts on target validation
and antibiotic lead identification until 2007 and Pfizer Animal Health’s platform
technology discovery efforts from 2007-2009.
Ken returned to MedImmune and the Biologicals field in 2009 to build and
lead new antibody discovery efforts focused on the prevention and treatment of serious
multidrug-resistant bacterial infections where his team’s efforts to date have
generated two clinical candidates, MEDI4893 targeting S. aureus and MEDI3902 targeting P. aeruginosa which are currently in phase 2 human clinical
studies.